Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5932_Библиотеки_им_академика_М_И_Перельмана

to lessen them is to employ liposomal DOXwith a relatively short half-life by using glucuronate instead of the sulfate counterion of the ammonium being used for remote loading. In tumor-bearing animals, the administration of glucuronate, which has a permeability coefcient equivalent to sulfate yet fails to cause intra-liposome drug deposition, causes DOXto circulate more quickly, albeit without sacricing its ther­apeutic efcacy [16,29]. Avery little but noticeable impact on the PK is anticipated to lessen the buildup of DOXin the skin, lessening the intensity of PPE. There are additional ways to enhance nano-liposome-based chemotherapyand have improved control over drug release, including 1. the use of external methods like intensive ultrasound or hyperthermia; 2. the use of drug combinations by remotely loading two medications that work synergistically inside one liposome; and 3. the pairing of two distinct therapeutic approaches, like Doxil® and interleukin-2 (IL-2) [30].

Docetaxel (DTX) is frequently utilized as an anticancer agent used alone or in com­bination for non-small cell pulmonary, ovarian, breast, gastrointestinal, neck, pros­tate, and throatcancers. Its tumor-ghting system is the suppression of the mitotic spindle through binding to microtubules, causing the spindle and microtubulesto stabilize [34,35]. While DTX is a powerful anticancer agent, a drug for the therapy of a variety of cancers in unique chemical entities at different phases, it also has a few unfavorable cytotoxic consequences [36]. In a clinical context, the most serious non-hematological side effects of any taxane cytotoxic drug are central neurotoxicity and hypersensitivity [37].

The effectiveness of the PNP encapsulated bydocetaxel (PNP-DTX) was evalu­ated by Song etal. (2016) in preclinical animal models, and the maximum tolerated dosage (MTD) was established using clinical testing [36]. Specialized mice models, such asorthotopic and subcutaneous, were employed for conducting the investiga­tion. Both the quantication of in-vivo imaging and the tumor development delay in the orthotopic model was assessed. Advanced tumors were the focus of a single­center, retrospective, open-label phase Iclinical investigation. Starting at 20 mg/m2, the intravenous injection of PNP-DTX was increased to 35 mg/m2, 45 mg/m2, 60 mg/ m2, and 75 mg/m2. In their study, the toxicities, tumor responses, and pharmacoki­netics were assessed effectively.

bicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospho­lipid: Pharmacokinetic studies in rodents and dogs, Pharm. Res. 10 (1993) 703–708. doi:10.1023/A:1018907715905.

[17] D. Peer (Ed.), Handbook of Harnessing Biomaterials in Nanomedicine, Jenny Stanford

Y. Barenholz, Prolonged circulation time and enhanced accumulation in malignant exu­dates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54 (1994) 987–92. http://www.ncbi.nlm.nih.gov/pubmed/8313389.

[20] Y. Barenholz, Relevancy of drug loading to liposomal formulation therapeutic efcacy,

324 Index